%PDF-1.4
%
81 0 obj
<>
endobj
78 0 obj
<>
endobj
134 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-06-03T16:19:15Z
2024-03-29T04:43:23-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T04:43:23-07:00
application/pdf
Heather
2004-712.july
uuid:fdad29e3-1dd1-11b2-0a00-130a27bd7700
uuid:fdad29e5-1dd1-11b2-0a00-900000000000
endstream
endobj
67 0 obj
<>
endobj
68 0 obj
<>
endobj
82 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 51 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 53 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 55 0 R/Type/Page>>
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 57 0 R/Type/Page>>
endobj
42 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 59 0 R/Type/Page>>
endobj
45 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 61 0 R/Type/Page>>
endobj
156 0 obj
[160 0 R]
endobj
157 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 736.1941 Tm
[(a modified Stanford Health )54.8 (Assessment Questionnaire. )54.8 (Arthritis)]TJ
0 Tc 0 -1.25 TD
(Rheum 1983;26:1346-53.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (W)79.9 (are JE, Sherbourne CD. )17.7 (The MOS 36-Item Short-Form Health)]TJ
1.675 -1.25 Td
(Survey \(SF-36\). 1. Conceptual framework and item selection. Med)Tj
T*
(Care 1992;30:473-83.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (W)79.9 (olfe F)79.7 (,)-0.1 ( )54.8 (Anderson J, Burke )17.7 (T)79.9 (A, )54.8 (Ar)17.7 (guelles LM, Pettitt D.)]TJ
1.675 -1.25 Td
(Gastroprotective therapy and risk of gastrointestinal ulcers: risk)Tj
T*
[(reduction by COX-2 therapy)64.8 (. J Rheumatol 2002;29:467-73.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (W)79.9 (olfe F)79.7 (, Flowers N, Burke )17.7 (T)79.9 (A, )54.8 (Ar)17.7 (guelles LM, Pettitt D. Increase in)]TJ
1.675 -1.25 Td
(lifetime adverse drug reactions, service utilization, and disease)Tj
T*
(severity among patients who will start COX-2 specific inhibitors:)Tj
T*
(quantitative assessment of channeling bias and confounding by)Tj
T*
(indication in 6689 patients with rheumatoid arthritis and)Tj
T*
(osteoarthritis. J Rheumatol 2002;29:1015-22.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Michaud K, Messer J, Choi HK, )17.7 (W)79.9 (olfe F)79.7 (. Direct medical costs and)]TJ
1.675 -1.25 Td
(their predictors in persons with rheumatoid arthritis: a 3 year study)Tj
T*
[(of 7,527 patients. )54.8 (Arthritis Rheum 2003;48:2750-62.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (McHorney CA, )17.7 (W)79.9 (are JE Jr)39.7 (, Lu JF)79.7 (, Sherbourne CD. )17.7 (The MOS )]TJ
1.675 -1.25 Td
[(36-item Short-Form Health Survey \(SF-36\): III. )17.7 (T)69.9 (ests of data )]TJ
T*
[(quality)64.8 (, scaling assumptions, and reliability across diverse patient)]TJ
T*
(groups. Med Care 1994;32:40-66.)Tj
31.325 25 Td
[(9.)-875.1 (Stucki G, Liang MH, Stucki S, Bruhlmann P)110.7 (, Michel BA. )54.8 (A)-220.1 (self-)]TJ
1.675 -1.25 Td
(administered rheumatoid arthritis disease activity index \(RADAI\))Tj
T*
(for epidemiologic research. Psychometric properties and correlation)Tj
T*
[(with parameters of disease activity)64.8 (. )54.8 (Arthritis Rheum 1995;38:795-8.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Newson R. Parameters beyond \322nonparametric\323 statistics: Kendall\325\
)54.8 (s)]TJ
2.175 -1.25 Td
[(tau, Somer)-37 (\325)55.1 (s D and median dif)17.7 (ferences. Stata Journal 2002;2:45-64.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Stata Corporation. Stata statistical software: release 8.2. College)]TJ
2.1381 -1.25 Td
[(Station, )17.7 (TX: Stata Corp.; 2003.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Linacre JM. Facets Rasch measurement computer program.)]TJ
2.175 -1.25 Td
[(Chicago: )17.7 (W)39.8 (insteps; 2004. )54.8 (A)74 (vaialble from: )17.7 (W)39.8 (insteps.com. )54.8 (Accessed)]TJ
0 Tc T*
(March 18, 2005.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875.1 (T)35 (ugwell P)110.7 (,)-0.1 ( )17.7 (W)79.9 (ells G, Strand )17.7 (V)128.9 (, et al. Clinical improvement as)]TJ
2.175 -1.25 Td
(reflected in measures of function and health- related quality of life)Tj
T*
(following treatment with leflunomide compared with methotrexate)Tj
T*
(in patients with rheumatoid arthritis: sensitivity and relative )Tj
T*
[(ef)17.7 (ficiency to detect a treatment ef)17.7 (fect in a twelve-month, )]TJ
T*
[(placebo-controlled trial. Leflunomide Rheumatoid )54.8 (Arthritis)]TJ
T*
[(Investigators Group. )54.8 (Arthritis Rheum 2000;43:506-14. [Erratum:)]TJ
T*
(Arthritis Rheum 2000;43:1345].)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Anderson JJ, Bolognese JA, Felson DT)73.9 (. Comparison of rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis clinical trial outcome measures: a simulation study)64.8 (.)]TJ
T*
(Arthritis Rheum 2003;48:3031-8.)Tj
ET
0 0 0 1 K
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 0 Tw 8 0 0 8 53.8216 56.7343 Tm
(1266)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:7)Tj
ET
0 0 0 0 k
/GS0 gs
103.631 82.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
103.631 82.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
61 0 obj
<>stream
8;Z\5#nFj,#ikq,oQR`%Z%8-7>.$`On>)YT0a9D+nRJdbp;?j9h-lhtheq%8bY):T
RGb.2=PM0+KI]7EU)8,Vk/%5ofNElg)+E[YFo537u$fm_2L7\e@E1`D?CUXcUlhN`W=]^C&A9T!rr=b/u&~>
endstream
endobj
65 0 obj
[/Indexed/DeviceRGB 255 64 0 R]
endobj
64 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
96 0 obj
<>
endobj
84 0 obj
<>
endobj
121 0 obj
<>
endobj
139 0 obj
<>
endobj
85 0 obj
<>
endobj
111 0 obj
<>stream
HtyPYǻ ݉A6Hݭ*^n
"#x (L8!B 4r'ꈫ2B8;ǜf^珙zUz5`8O
NViP&Fח
.<#\[c\x-E?~LbygC|0%5mg/
IMiԻ3q~\@F14jXAP%kU)qT2Cん\Jd csj-24xURKM)4)SԂ63VW+5jwՎS>y1M#9a l'
bl&l>N̉o]Vwy-(=:b!a%~$ĸxZ2Kjf<ᄮ oɉ9Hcg3)sCvNcj9Y6Y7:5Ϋ
ѐ߹!!?>